Stocktoria
VERACYTE, INC. VCYT
Nasdaq · XNAS · stock · Services-Medical Laboratories · website · IPO 2013-10-30
VERACYTE, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 70.1% | 66.9% | 63.6% | 59.2% | — |
| Operating margin | 11.2% | 3.6% | -23.8% | -13.9% | -37.3% |
| Net margin | 12.8% | 5.4% | -20.6% | -12.3% | -34.4% |
| FCF margin | 24.5% | 14.3% | 9.5% | -0.3% | -16.9% |
| Return on assets | 4.7% | 1.9% | -6.7% | -3.2% | -6.4% |
| Return on equity | 5.1% | 2.1% | -7.1% | -3.4% | -6.9% |
| Debt / equity | — | — | — | — | 0.00× |
| Current ratio | 8.15 | 4.73 | 4.66 | 3.97 | 3.79 |
| Revenue growth | 16.0% | 23.5% | 21.8% | 35.1% | 86.8% |
Source: SEC EDGAR filings · CIK 0001384101 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.